VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease.

50 A training effect could partially explain the MMSE score increase, but such an effect may not be significant among cognitively impaired individuals; the MMSE training effect with administration at a 2.3‐day interval was 0.28 points in another study. 43 This trial demonstrated that a 4‐week high‐dose oral valacyclovir regimen was feasible, tolerable, and safe for patients with early‐stage AD, HSV, and APOE ε4.

also in 2,774 other papers